Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.

ABSTRACT: Since the early 1990s the Developmental Therapeutics Program of the National Cancer Institute (NCI) has utilized a panel of 60 human tumor cell lines (NCI60) representing 9 tissue types to screen for potential new anticancer agents. To date, about 100,000 compounds and 50,000 natural product extracts have been screened. Early in this program it was discovered that the pattern of growth inhibition in these cell lines was similar for compounds of similar mechanism. The development of the COMPARE algorithm provided a means by which investigators, starting with a compound of interest, could identify other compounds whose pattern of growth inhibition was similar. With extensive molecular characterization of these cell lines, COMPARE and other user-defined algorithms have been used to link patte

SUBMITTER: Holbeck SL 

PROVIDER: S-EPMC2868078 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature